Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
at 12 months in first-line pancreatic cancer patients, with no new safety signals identified as of the December 15, 2025 cutoff. A key nuance is that these results, though compared against MPACT standard-of-care benchmarks, come from a relatively small 34-patient, non–head-to-head trial that will now inform the design of the planned pivotal Phase 3 MAPKeeper 301 study. We'll now examine how these early pancreatic cancer survival data and the planned mid-2026 Phase 3 trial could shape Immuneering's investment narrative. These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Immuneering today, you have to believe its “all-in” bet on atebimetinib can eventually translate strong early pancreatic cancer data into an approved product, despite zero revenue and ongoing losses. The updated Phase 2a readout, with 12-month survival and safety holding up, reinforce
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]Yahoo! Finance
- Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]Seeking Alpha
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPGlobeNewswire
- Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]Seeking Alpha
- Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]Yahoo! Finance
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 1/16/26 - Form 4
- 1/15/26 - Form SCHEDULE
- 1/15/26 - Form 4
- IMRX's page on the SEC website